Jason Ehrlich - 20 Oct 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 Oct 2021, 16:52:24 UTC
Prior SEC filing
22 Sep 2021
Next SEC filing
24 Nov 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich

Key filing fact

Jason Ehrlich filed Form 4 for Kodiak Sciences Inc. (KOD) on 22 Oct 2021.

Key facts

  • This page summarizes Jason Ehrlich's Form 4 filing for Kodiak Sciences Inc. (KOD).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 22 Oct 2021, 16:52.

Change

  • Previous filing in this sequence was filed on 22 Sep 2021.
  • Current net transaction value: -$705,309.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KOD transaction

Common Stock

Options Exercise

Transaction value
$71,516
Shares
+6,950
Change %
+13%
Price
$10.29
Shares after
58,491
Date
20 Oct 2021
Ownership
Direct
KOD transaction

Common Stock

Sale

Transaction value
$635,681
Shares
-5,698
Change %
-9.7%
Price
$111.56*
Shares after
52,793
Date
20 Oct 2021
Ownership
Direct
Footnotes
F1, F2
KOD transaction

Common Stock

Sale

Transaction value
$141,144
Shares
-1,252
Change %
-2.4%
Price
$112.73*
Shares after
51,541
Date
20 Oct 2021
Ownership
Direct
Footnotes
F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KOD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-6,950
Change %
-2.8%
Price
$0.000000
Shares after
239,388
Date
20 Oct 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,950
Exercise price
$10.29
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

Footnote F2

The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $111.16 to $112.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

Footnote F3

The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $112.23 to $113.16, inclusive.

Footnote F4

Twenty-five percent of the shares subject to the option vested on September 1, 2019, and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC remarks

Chief Medical Officer and Chief Development Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .